NON-ALCOHOLIC STEATOHEPATITIS

This study tested whether a pill called idebenone is safe and might help people with a serious fatty liver disease called NASH. It involved 53 adults with early to moderate liver scarring. Participants took either the study drug or a placebo for up to a year to see if the drug co…

This early-stage study tested a new drug called ARO-HSD to see if it is safe and how it behaves in the body. It involved 50 healthy volunteers and patients with a serious form of fatty liver disease called NASH. The main goal was to check for side effects and measure how the drug…

This study tested whether a daily oral medication called MGL-3196 could reduce the amount of fat in the liver for people with NASH, a serious form of fatty liver disease. It involved 125 adults with confirmed NASH and measured changes in liver fat using special MRI scans over 12 …

This study tested whether combining a new liver-targeted medicine with an existing diabetes/weight-loss drug could better treat NASH, a serious form of fatty liver disease that causes scarring. About 700 adults with confirmed NASH and liver scarring received weekly injections of …

This early-stage study tested a new oral drug called J2H-1702, which is being developed to treat non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to check the drug's safety, how the body processes it, and how well it was tolerated in …

This study tested a new drug called J2H-1702 for people with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. 87 participants received either one of three doses of the drug or a placebo for 12 weeks. The main goals were to check the drug's safety and s…

This study tested a new ultrasound feature to see if it could measure liver fat in children as accurately as a standard MRI scan. It involved 30 children and teens at risk for or diagnosed with fatty liver disease. Each participant received both an investigational ultrasound and …

This study tested a new ultrasound feature to see if it could measure fat in the liver as well as a standard MRI scan. It involved 60 adults who were at risk for or had non-alcoholic fatty liver disease (NAFLD). Each participant had two special ultrasound exams and one MRI scan t…

This study tested how consistent and reliable a special type of MRI scan, called LiverMultiScan, is for measuring liver health. Researchers scanned 61 volunteers with various liver conditions on different MRI machines to see if the results were the same each time. The goal is to …

This study looked back at the medical records of 263 adults with a confirmed liver disease called NASH to see if certain patient characteristics, other health conditions, or medications were linked to more severe liver scarring. Researchers analyzed data from 2013 to 2020 to iden…

This study aimed to understand how a drug for fatty liver disease (NASH) is processed by the body in people with moderate to severe liver damage. Researchers compared 22 participants—some with liver impairment and some healthy—after they received a single dose. The main goal was …

This was an early-stage safety study for a potential new medicine called ACT500, which is being developed for a serious liver condition called non-alcoholic steatohepatitis (NASH). The study tested single and multiple doses in 72 healthy Chinese adults to see how safe the drug wa…

This was a very early, first-in-human study to see if a single dose of a potential new medicine called J2H-1702 is safe for people. It involved 16 healthy female volunteers to check for side effects and measure how the drug moves through the body. The goal was to gather basic saf…